Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Rieken, M; Kluth, LA; Xylinas, E; Fajkovic, H; Becker, A; Karakiewicz, PI; Herman, M; Lotan, Y; Seitz, C; Schramek, P; Remzi, M; Loidl, W; Pummer, K; Lee, RK; Faison, T; Scherr, DS; Kautzky-Willer, A; Bachmann, A; Tewari, A; Shariat, SF.
Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer.
World J Urol. 2014; 32(4):999-1005
Doi: 10.1007/s00345-013-1171-7
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Pummer Karl
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The impact of diabetes mellitus (DM) and metformin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial. We retrospectively evaluated 6,863 patients who underwent RP for clinically localized PC between 2000 and 2011. Univariable and multivariable Cox regression models addressed the association of DM and metformin use with BCR. Overall, 664 patients had a diagnosis of DM from which 287 (43 %) were on metformin and 377 (57 %) were on anti-diabetics other than metformin. DM and metformin were not associated with any clinicopathologic features (p values >0.05). Within a median follow-up of 25 months (interquartile range 35 months), 774 (11.3 %) patients experienced BCR. Actuarial 5-year biochemical-free survival was 83 % for non-diabetic, 79 % for diabetic patients without metformin use, and 85 % for diabetic patients with metformin use (log rank p = 0.17). In uni- and multivariable Cox regression analyses with the non-diabetic group as referent, DM without metformin use (HR = 0.99; 95 % CI 0.75-1.30, p = 0.65) and DM with metformin use (HR = 0.84, 95 % CI 0.58-1.22, p = 0.36) were not associated with BCR after RP. A subgroup analysis stratified by nodal status, surgical margins, tumor stage, and Gleason sum did not reveal any significant association between DM, use of metformin and risk of BCR. We found no association between DM or metformin use and cancer-specific features or BCR in patients treated with RP. The effect of DM and metformin on complications, wound healing and overall survival needs to be assessed in similar cohorts.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Diabetes Mellitus - drug therapy
- Follow-Up Studies -
- Humans -
- Hypoglycemic Agents - therapeutic use
- Insulin-Like Growth Factor I - metabolism
- Male -
- Metformin - therapeutic use
- Middle Aged -
- Prostate-Specific Antigen - blood
- Prostatectomy -
- Prostatic Neoplasms - blood
- Prostatic Neoplasms - surgery
- Recurrence -
- Regression Analysis -
- Retrospective Studies -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- Prostate cancer
- Radical prostatectomy
- Diabetes mellitus
- Metformin
- Biochemical recurrence